The Detrimental Effects of Oral Vancomycin.

The Detrimental Effects of Oral Vancomycin.
复制标题

口服万古霉素的有害影响。

DOI:
10.1093/cid/ciaa1504
复制
发表时间:
2021
期刊:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子:
--
通讯作者:
Taur,Ying
Taur,Ying
中科院分区:
--
文献类型:
--
作者:
Peled,JonathanU;Taur,Ying

文献摘要

参考文献

相似文献

致编辑:我们饶有兴趣地阅读了希瑟和雷兹对我们最近刊物的评论。鉴于这是确定乌干达公共卫生系统中病毒载量(VL)为1000拷贝/mL的疑似抗逆转录病毒治疗(ART)患者中隐球菌抗原(CrAg)流行率的首批研究之一,我们得出的结论在实施国家规划指南方面可能被夸大了。我们同意,我们只有少数患者可以证明结果的改善,然而,尽管我们的研究人数很少,但根据乌干达和南非的先前研究,对隐球菌抗原血症患者进行预防性抗真菌治疗后,CrAg患病率为>.6 %是具有成本效益的[1,2]。我们认为,在VL为1000拷贝/mL的个体中,crg患病率为3%,因此有必要进行更大规模的评估研究,特别是在撒哈拉以南非洲,隐球菌病仍然是艾滋病相关死亡的重要原因。其次,鉴于出现隐球菌性脑膜炎的艾滋病毒感染者的比例越来越倾向于接受过抗逆转录病毒治疗的人,有必要通过使用VL测试作为crg筛查切入点,对可能未能接受抗逆转录病毒治疗的人群中的crg患病率进行研究
To the Editor—We have read the commentary by Heather and Raizes on our recent publication with interest. Given that this was one of the first studies to determine cryptococcal antigen (CrAg) prevalence among individuals with suspected antiretroviral therapy (ART) with a viral load (VL)> 1000 copies/mL in the public health system in Uganda, the conclusions we draw may have been overstated in relation to implementing this guidance for country programs.We agree that we had small numbers of patients to demonstrate improvement in outcomes, however, despite the small numbers in our study, and based on prior studies in Uganda and South Africa, a CrAg prevalence of> 0.6% followed by pre-emptive antifungal therapy for those with cryptococcal antigenemia is cost effective [1, 2]. We believe that a CrAg prevalence of 3% among individuals with VL> 1000 copies/mL warrants the need to do larger evaluation studies, particularly in sub-Saharan Africa where cryptococcal disease remains a significant cause of AIDS-related mortality. Second, given that the proportion of HIV-infected individuals presenting with cryptococcal meningitis is increasingly skewed to those who are ART experienced, there is a need to do studies on CrAg prevalence among this population of individuals likely failing their ART regimen by using the VL test as a Crag screening entry point to define the
人催乳素:分离和一些特性。
DOI: --
发表时间: 1971
期刊: Biochemical and Biophysical Research Communications - BBRC
影响因子: --
作者:
U. Lewis;M. S. Singh;B. K. Seavey
通讯作者: B. K. Seavey
DOI: 10.1210/jcem-51-5-1058
发表时间: 1980-01-01
影响因子: 5.8
作者:
TANAKA, T;SHIU, RPC;FRIESEN, HG
通讯作者: FRIESEN, HG
人类子宫肌层:催乳素的新潜在来源。
DOI: --
发表时间: 1983
影响因子: 9.8
作者:
C. Walters;C. Walters;Douglas C. Daly;Douglas C. Daly;J. Chapitis;J. Chapitis;S. Kuslis;S. Kuslis;J. Prior;J. Prior;W. F. Kusmik;W. F. Kusmik;D. Riddick;D. Riddick
通讯作者: D. Riddick
催乳素:基本和临床相关性
DOI: --
发表时间: 1985
期刊:
影响因子: --
作者:
R. Macleod;M. Thorner;U. Scapagnini
通讯作者: U. Scapagnini
血浆和垂体提取物中人催乳素的大小异质性。
DOI: --
发表时间: 1974
影响因子: 5.8
作者:
H. Suh;A. Frantz
通讯作者: A. Frantz